<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00277862</url>
  </required_header>
  <id_info>
    <org_study_id>G43230832638</org_study_id>
    <nct_id>NCT00277862</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4</brief_title>
  <official_title>Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fulbright</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TEMPUS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Society for Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genotype 4 is the least-studied hepatitis C virus genotype and was considered a difficult to
      treat genotype due to the disappointing response of chronic hepatitis C genotype 4 to
      conventional interferon monotherapy. Recent reports showed that pegylated interferon and
      ribavirin combination therapy markedly increased the SVR rate to 55-70%. The duration of
      treatment has not been accurately defined. The main objective of this is to assess the
      duration of pegylated interferon ribavirin therapy in chronic hepatitis genotype 4 and assess
      the clinical utility of rapid and early virologic response in determining the optimal
      duration of peg interferon ribavirin therapy in chronic hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C virus (HCV) genotype 4 is the most frequent cause of chronic hepatitis C in
      Middle East, North Africa and sub-Saharan Africa. In countries like Egypt, 73 to 90% of cases
      of chronic hepatitis C are caused by genotype 4. Recently, epidemiological reports showed
      spread of HCV-4 infection in Western countries such as France, Italy, Greece, Spain and the
      United States particularly among intravenous drug users.

      Genotype 4 is the least-studied hepatitis C virus genotype and was considered a difficult to
      treat genotype due to the disappointing response of chronic hepatitis C genotype 4 to
      conventional interferon monotherapy. Recent reports showed that pegylated interferon and
      ribavirin combination therapy markedly increased the SVR rate to 55-70%. We have previously
      shown that, treatment patients with chronic HVCG4with PEG-IFN α-2b plus ribavirin for 36 or
      48 weeks was more effective (SVR 66% and 69%, respectively) than for 24 weeks.

      It has been shown in previous studies on chronic hepatitis C genotype 1 that individuals who
      achieve an early virologic have a higher chance to achieve a sustained virologic response.
      Peg interferon and ribavirin therapy is associated with adverse events and is expensive;
      therefore, careful determination of the optimal treatment duration is crucial as it spares
      the patient unnecessary or prolonged therapy and enhances the cost-effectiveness of therapy.

      Therefore the main objective of this randomized, multicenter trial is to assess the clinical
      utility of rapid and early virologic response in determining the optimal duration of peg
      interferon ribavirin therapy in chronic hepatitis C.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sustained virologic response defined as undetectable serum HCV RNA levels (Amplicor HCV, Roche Molecular Systems; lower limit of detection (LLD) of 50 IU/mL)</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic response at the end of treatment (EOT) defined as undetectable HCV RNA serum levels (50 IU/ml) at the end of the scheduled treatment period</measure>
    <time_frame>6-12 months and 6 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sustained virologic response (primary) histological response (secondary) biochemical response (secondary)</measure>
    <time_frame>6-12 months treatment), 6 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated IFN- alpha 2b
Ribavirin for 24 weeks (patients with RVR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated IFN- alpha 2b
Ribavirin for 36 weeks (patients with complete EVR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated IFN- alpha 2b
Ribavirin for 48 weeks (patients with partial EVR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated IFN- alpha 2b
Ribavirin for 48 weeks (control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated IFN- alpha 2b</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>PEG-IFN alpha-2b</other_name>
    <other_name>PEG-Intron™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Rebetol</other_name>
    <other_name>Virin</other_name>
    <other_name>Ribavrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Adult males and females, 18 to 50 years of age; with documented chronic
        hepatitis C according to the following criteria: elevated serum alanine aminotransferase
        (ALT) above the upper limit of normal (40 U/l) on two occasions during the preceding six
        months; anti-HCV positive anti-body status assessed by second generation enzyme linked
        immunosorbent assay (Roche Diagnostics, Branchburg, New Jersey, USA); positive polymerase
        chain reaction for HCV RNA (Cobas Amplicor HCV Monitor v2.0; lower limit of quantitation 50
        IU/mL); genotype 4; and criteria for chronic hepatitis C in liver biopsy performed within
        the preceding year with no signs of cirrhosis or bridging fibrosis on pretreatment liver
        biopsy.

        Exclusion Criteria:

          -  Previous IFN-alpha therapy; other liver diseases such as hepatitis A, hepatitis B,
             schistosomiasis, autoimmune hepatitis, alcoholic liver disease, drug induced
             hepatitis, or decompensated liver disease; coinfection with schistosomiasis or human
             immunodeficiency virus; neutro¬penia (,1 500/mm3); thrombocytopenia (,90 000/mm3);
             creatinine concentration .1.5 times the upper limit of normal; serum a fetoprotein
             concentration .25 ng/ml; organ transplant; neoplastic disease; severe cardiac or
             pulmonary disease; unstable thyroid dysfunction; psychiatric disorder; current
             pregnancy or breast feeding; or therapy with immunomodulatory agents within the last
             six months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanaa M Kamal, M.D.; Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>AUS Specialized Hospital, Cairo, Cairo, 11351, Egypt;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amany Sayed Ahmad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DIAGSERA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samer El Kamary</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amal Abdel Baky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DIGSERA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AUS Specialized Hospital,</name>
      <address>
        <city>Cairo;</city>
        <state>Cairo,</state>
        <zip>11351,</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIACSERA</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MISR Welding</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ELectricity Auth</name>
      <address>
        <city>Mynia and Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005 Jun;54(6):858-66.</citation>
    <PMID>15888797</PMID>
  </reference>
  <reference>
    <citation>Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002 Oct;123(4):1070-83.</citation>
    <PMID>12360469</PMID>
  </reference>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2006</study_first_submitted>
  <study_first_submitted_qc>January 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>February 25, 2008</last_update_submitted>
  <last_update_submitted_qc>February 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Nelly Sedky, Dr. Gehan Galal</name_title>
    <organization>DIAGSERA</organization>
  </responsible_party>
  <keyword>chronic hepatitis C;</keyword>
  <keyword>peg-interferon alfa-2b;</keyword>
  <keyword>ribavirin,</keyword>
  <keyword>rapid virologic response,</keyword>
  <keyword>sustained virological response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

